{"protocolSection": {"identificationModule": {"nctId": "NCT02739984", "orgStudyIdInfo": {"id": "20130287"}, "secondaryIdInfos": [{"id": "2015-004711-21", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia", "officialTitle": "A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia", "acronym": "BANTING"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-05-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-08-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-04-12", "studyFirstSubmitQcDate": "2016-04-12", "studyFirstPostDateStruct": {"date": "2016-04-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-02", "resultsFirstSubmitQcDate": "2018-08-02", "resultsFirstPostDateStruct": {"date": "2018-08-31", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-02", "lastUpdatePostDateStruct": {"date": "2018-08-31", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.", "detailedDescription": "This study will enroll adults with type 2 diabetes mellitus and elevated LDL-C or non-high-density lipoprotein cholesterol (non-HDL-C) levels on a stable, maximally tolerated statin dose of at least moderate-intensity at signing of the informed consent; statin therapy must remain unchanged during screening and the remainder of the study."}, "conditionsModule": {"conditions": ["Hypercholesterolemia", "Mixed Dyslipidemia", "Type 2 Diabetes"], "keywords": ["diabetes", "type 2 diabetes", "high blood cholesterol", "hypercholesterolemia", "mixed dyslipidemia", "high cholesterol", "statin intolerant"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 424, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.", "interventionNames": ["Drug: Placebo to Evolocumab"]}, {"label": "Evolocumab", "type": "EXPERIMENTAL", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.", "interventionNames": ["Biological: Evolocumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Evolocumab", "description": "Administered by subcutaneous injection with an automated mini doser", "armGroupLabels": ["Evolocumab"], "otherNames": ["Repatha", "AMG 145"]}, {"type": "DRUG", "name": "Placebo to Evolocumab", "description": "Administered by subcutaneous injection with an automated mini doser", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and Weeks 10 and 12"}, {"measure": "Percent Change From Baseline in LDL-C at Week 12", "timeFrame": "Baseline and week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in LDL-C at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Change From Baseline in LDL-C at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in Non-HDL-C at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in Apolipoprotein B at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in Total Cholesterol at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)", "timeFrame": "Weeks 10 and 12"}, {"measure": "Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)", "timeFrame": "Week 12"}, {"measure": "Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12", "timeFrame": "Baseline and Week 12"}, {"measure": "Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in Lipoprotein(a) at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in Triglycerides at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in HDL-C at Week 12", "timeFrame": "Baseline and week 12"}, {"measure": "Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12", "timeFrame": "Baseline and weeks 10 and 12"}, {"measure": "Percent Change From Baseline in VLDL-C at Week 12", "timeFrame": "Baseline and week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female \u2265 18 years\n* Type 2 Diabetes Mellitus\n* Hemoglobin A1c \\< 10%\n* Stable diabetes therapy\n* Must be on maximally tolerated dose of statin of at least moderate Intensity\n* Fasting triglycerides \u2264 600 mg/dL\n* Not at LDL-C or Non-HDL-C goal.\n\nExclusion Criteria:\n\n* Moderate to severe renal dysfunction\n* Uncontrolled hypertension\n* Persistent active liver disease or hepatic dysfunction\n* Has taken a cholesterylester transfer protein inhibitor in the last 12 months,\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Tuscumbia", "state": "Alabama", "zip": "35674", "country": "United States", "geoPoint": {"lat": 34.7312, "lon": -87.70253}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "zip": "85012", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Lomita", "state": "California", "zip": "90717", "country": "United States", "geoPoint": {"lat": 33.79224, "lon": -118.31507}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Research Site", "city": "San Ramon", "state": "California", "zip": "94583", "country": "United States", "geoPoint": {"lat": 37.77993, "lon": -121.97802}}, {"facility": "Research Site", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "Research Site", "city": "Tarzana", "state": "California", "zip": "91356", "country": "United States", "geoPoint": {"lat": 34.17334, "lon": -118.55397}}, {"facility": "Research Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Lakewood", "state": "Colorado", "zip": "80227", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Research Site", "city": "Wilmington", "state": "Delaware", "zip": "19803", "country": "United States", "geoPoint": {"lat": 39.74595, "lon": -75.54659}}, {"facility": "Research Site", "city": "Boca Raton", "state": "Florida", "zip": "33434", "country": "United States", "geoPoint": {"lat": 26.3669, "lon": -80.13033}}, {"facility": "Research Site", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Research Site", "city": "Daytona Beach", "state": "Florida", "zip": "32117", "country": "United States", "geoPoint": {"lat": 29.21081, "lon": -81.02283}}, {"facility": "Research Site", "city": "Fleming Island", "state": "Florida", "zip": "32003", "country": "United States", "geoPoint": {"lat": 30.0933, "lon": -81.71898}}, {"facility": "Research Site", "city": "Hollywood", "state": "Florida", "zip": "33021", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Research Site", "city": "Inverness", "state": "Florida", "zip": "34452", "country": "United States", "geoPoint": {"lat": 28.83582, "lon": -82.33037}}, {"facility": "Research Site", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33135", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "West Palm Beach", "state": "Florida", "zip": "33401", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Research Site", "city": "Dunwoody", "state": "Georgia", "zip": "30338", "country": "United States", "geoPoint": {"lat": 33.94621, "lon": -84.33465}}, {"facility": "Research Site", "city": "Meridian", "state": "Idaho", "zip": "83642", "country": "United States", "geoPoint": {"lat": 43.61211, "lon": -116.39151}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60616", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Louisville", "state": "Kentucky", "zip": "40213", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Research Site", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "Research Site", "city": "Scarborough", "state": "Maine", "zip": "04074", "country": "United States", "geoPoint": {"lat": 43.57814, "lon": -70.32172}}, {"facility": "Research Site", "city": "Salisbury", "state": "Maryland", "zip": "21804", "country": "United States", "geoPoint": {"lat": 38.36067, "lon": -75.59937}}, {"facility": "Research Site", "city": "Methuen", "state": "Massachusetts", "zip": "01844", "country": "United States", "geoPoint": {"lat": 42.7262, "lon": -71.19089}}, {"facility": "Research Site", "city": "Bay City", "state": "Michigan", "zip": "48706", "country": "United States", "geoPoint": {"lat": 43.59447, "lon": -83.88886}}, {"facility": "Research Site", "city": "Tupelo", "state": "Mississippi", "zip": "38801", "country": "United States", "geoPoint": {"lat": 34.25807, "lon": -88.70464}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87106", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Site", "city": "New Windsor", "state": "New York", "zip": "12553", "country": "United States", "geoPoint": {"lat": 41.47676, "lon": -74.02375}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Shelby", "state": "North Carolina", "zip": "28150", "country": "United States", "geoPoint": {"lat": 35.29235, "lon": -81.53565}}, {"facility": "Research Site", "city": "Tabor City", "state": "North Carolina", "zip": "28463", "country": "United States", "geoPoint": {"lat": 34.14878, "lon": -78.87669}}, {"facility": "Research Site", "city": "Columbus", "state": "Ohio", "zip": "43203", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Research Site", "city": "Norman", "state": "Oklahoma", "zip": "73069", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"facility": "Research Site", "city": "Austin", "state": "Texas", "zip": "78749", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77070", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Suffolk", "state": "Virginia", "zip": "23435", "country": "United States", "geoPoint": {"lat": 36.72836, "lon": -76.58496}}, {"facility": "Research Site", "city": "Edegem", "zip": "2650", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"facility": "Research Site", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Research Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Y 3W2", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Gatineau", "state": "Quebec", "zip": "J8Y 6S8", "country": "Canada", "geoPoint": {"lat": 45.47723, "lon": -75.70164}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H1Y 3L1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "St-J\u00e9r\u00f4me", "state": "Quebec", "zip": "J7Z 5T3", "country": "Canada", "geoPoint": {"lat": 45.78036, "lon": -74.00365}}, {"facility": "Research Site", "city": "Roma", "zip": "00128", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Roma", "zip": "00133", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Verona", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Research Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44600", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Chihuahua", "zip": "31217", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Research Site", "city": "Katowice", "zip": "40-040", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-315", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Warszawa", "zip": "02-018", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Wroclaw", "zip": "50-306", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Almeria", "state": "Andaluc\u00eda", "zip": "04001", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Research Site", "city": "Granada", "state": "Andaluc\u00eda", "zip": "18016", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "Research Site", "city": "Badalona", "state": "Catalu\u00f1a", "zip": "08916", "country": "Spain", "geoPoint": {"lat": 41.45004, "lon": 2.24741}}, {"facility": "Research Site", "city": "Barcelona", "state": "Catalu\u00f1a", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}]}, "referencesModule": {"references": [{"pmid": "30953107", "type": "DERIVED", "citation": "Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 Jun;62(6):948-958. doi: 10.1007/s00125-019-4856-7. Epub 2019 Apr 5."}], "seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants received subcutaneous placebo during a 6-week screening period. Participants who completed the screening period and met final eligibility criteria were randomized in a 1:2 ratio to placebo or evolocumab. Randomization was stratified by low-density lipoprotein cholesterol (LDL-C) level (\\> or \\< 130 mg/dL).", "recruitmentDetails": "Of 853 patients screened, a total of 424 participants were randomized at 58 centers in Belgium, Canada, Italy, Mexico, Poland, Spain and the United States from 17 May 2016 to 05 May 2017.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "FG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "143"}, {"groupId": "FG001", "numSubjects": "281"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "141"}, {"groupId": "FG001", "numSubjects": "280"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "279"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants", "groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "BG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "62.3", "spread": "8.5"}, {"groupId": "BG001", "value": "62.5", "spread": "8.5"}, {"groupId": "BG002", "value": "62.5", "spread": "8.5"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"title": "< 65 years", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "159"}, {"groupId": "BG002", "value": "245"}]}, {"title": "65 - < 85 years", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "179"}]}, {"title": "\u2265 85 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "186"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "160"}, {"groupId": "BG002", "value": "238"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "78"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "227"}, {"groupId": "BG002", "value": "346"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Black (or African American)", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "73"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "223"}, {"groupId": "BG002", "value": "325"}]}, {"title": "Multiple", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "424"}]}], "categories": [{"title": "< 130 mg/dL", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "213"}, {"groupId": "BG002", "value": "321"}]}, {"title": "\u2265 130 mg/dL", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "103"}]}]}]}, {"title": "LDL-C Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "421"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "110.4", "spread": "33.0"}, {"groupId": "BG001", "value": "108.6", "spread": "31.0"}, {"groupId": "BG002", "value": "109.2", "spread": "31.6"}]}]}]}, {"title": "Non-High-density Lipoprotein Cholesterol (non-HDL-C) Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "421"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "145.5", "spread": "33.9"}, {"groupId": "BG001", "value": "144.6", "spread": "34.9"}, {"groupId": "BG002", "value": "144.9", "spread": "34.5"}]}]}]}, {"title": "Apolipoprotein B Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab) and with available baseline data.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "98.1", "spread": "22.1"}, {"groupId": "BG001", "value": "97.1", "spread": "23.3"}, {"groupId": "BG002", "value": "97.5", "spread": "22.9"}]}]}]}, {"title": "Total Cholesterol Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "421"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "190.7", "spread": "35.0"}, {"groupId": "BG001", "value": "188.2", "spread": "36.8"}, {"groupId": "BG002", "value": "189.1", "spread": "36.2"}]}]}]}, {"title": "Lipoprotein(a) Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab) and with available baseline data.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nmol/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "137"}, {"groupId": "BG001", "value": "273"}, {"groupId": "BG002", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "99.4", "spread": "122.8"}, {"groupId": "BG001", "value": "88.0", "spread": "111.5"}, {"groupId": "BG002", "value": "91.8", "spread": "115.4"}]}]}]}, {"title": "Triglycerides Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "421"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "177.3", "spread": "89.2"}, {"groupId": "BG001", "value": "184.2", "spread": "102.2"}, {"groupId": "BG002", "value": "181.9", "spread": "98.0"}]}]}]}, {"title": "High-density Lipoprotein Cholesterol (HDL-C) Concentraion", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "421"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "45.2", "spread": "12.2"}, {"groupId": "BG001", "value": "43.6", "spread": "12.9"}, {"groupId": "BG002", "value": "44.2", "spread": "12.7"}]}]}]}, {"title": "Very Low-density Lipoprotein Cholesterol (VLDL-C) Concentration", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab) and with available baseline data.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "276"}, {"groupId": "BG002", "value": "414"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33.6", "spread": "14.3"}, {"groupId": "BG001", "value": "34.8", "spread": "15.4"}, {"groupId": "BG002", "value": "34.4", "spread": "15.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and Weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "1.76"}, {"groupId": "OG001", "value": "-64.98", "spread": "1.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-64.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-68.16", "ciUpperLimit": "-60.12", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.05", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "PRIMARY", "title": "Percent Change From Baseline in LDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.14", "spread": "1.92"}, {"groupId": "OG001", "value": "-54.28", "spread": "1.42"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-53.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-57.56", "ciUpperLimit": "-48.71", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.25", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in LDL-C at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3", "spread": "2.2"}, {"groupId": "OG001", "value": "-75.5", "spread": "1.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-67.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-72.1", "ciUpperLimit": "-62.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.5", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in LDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.6", "spread": "2.3"}, {"groupId": "OG001", "value": "-64.4", "spread": "1.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-55.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-61.0", "ciUpperLimit": "-50.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.7", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "1.63"}, {"groupId": "OG001", "value": "-56.62", "spread": "1.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-56.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-60.28", "ciUpperLimit": "-52.85", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.89", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Non-HDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "1.79"}, {"groupId": "OG001", "value": "-46.89", "spread": "1.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-46.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-50.42", "ciUpperLimit": "-42.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.10", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.31", "spread": "1.58"}, {"groupId": "OG001", "value": "-50.17", "spread": "1.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-52.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-56.10", "ciUpperLimit": "-48.85", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.85", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Apolipoprotein B at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.78", "spread": "1.73"}, {"groupId": "OG001", "value": "-40.34", "spread": "1.29"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-42.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-46.13", "ciUpperLimit": "-38.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.04", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.13", "spread": "1.24"}, {"groupId": "OG001", "value": "-42.19", "spread": "0.92"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-41.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-43.90", "ciUpperLimit": "-38.22", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.44", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Total Cholesterol at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.23", "spread": "1.36"}, {"groupId": "OG001", "value": "-34.97", "spread": "1.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-33.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.87", "ciUpperLimit": "-30.60", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.59", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.8", "lowerLimit": "9.8", "upperLimit": "21.8"}, {"groupId": "OG001", "value": "92.7", "lowerLimit": "89.0", "upperLimit": "95.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Cochran Mantel Haenszel (CMH) test adjusted by the stratification factor (screening LDL-C level).", "paramType": "Treatment Difference", "paramValue": "77.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "70.0", "ciUpperLimit": "83.5", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "lowerLimit": "10.2", "upperLimit": "22.6"}, {"groupId": "OG001", "value": "84.5", "lowerLimit": "79.5", "upperLimit": "88.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Cochran Mantel Haenszel (CMH) test adjusted by the stratification factor (screening LDL-C level).", "paramType": "Treatment Difference", "paramValue": "69.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "60.4", "ciUpperLimit": "75.7", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "lowerLimit": "0.1", "upperLimit": "4.1"}, {"groupId": "OG001", "value": "84.2", "lowerLimit": "79.5", "upperLimit": "88.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Cochran Mantel Haenszel (CMH) test adjusted by the stratification factor (screening LDL-C level).", "paramType": "Treatment Difference", "paramValue": "83.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "77.7", "ciUpperLimit": "87.4", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "lowerLimit": "0.1", "upperLimit": "4.2"}, {"groupId": "OG001", "value": "65.5", "lowerLimit": "59.4", "upperLimit": "71.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Cochran Mantel Haenszel (CMH) test adjusted by the stratification factor (screening LDL-C level).", "paramType": "Treatment Difference", "paramValue": "64.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "57.7", "ciUpperLimit": "70.3", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.63", "spread": "3.29"}, {"groupId": "OG001", "value": "-30.87", "spread": "2.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-40.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-48.11", "ciUpperLimit": "-32.90", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.87", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Lipoprotein(a) at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.38", "spread": "3.06"}, {"groupId": "OG001", "value": "-25.18", "spread": "2.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-32.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.58", "ciUpperLimit": "-25.53", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.57", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.61", "spread": "2.94"}, {"groupId": "OG001", "value": "-12.64", "spread": "2.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-19.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.95", "ciUpperLimit": "-12.54", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.41", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Triglycerides at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.81", "spread": "3.41"}, {"groupId": "OG001", "value": "-8.90", "spread": "2.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-13.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.60", "ciUpperLimit": "-5.80", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.02", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.57", "spread": "1.25"}, {"groupId": "OG001", "value": "7.23", "spread": "0.93"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "9.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.95", "ciUpperLimit": "12.64", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.45", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in HDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.41", "spread": "1.38"}, {"groupId": "OG001", "value": "5.96", "spread": "1.02"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "7.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.19", "ciUpperLimit": "10.56", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.62", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and weeks 10 and 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.42", "spread": "2.57"}, {"groupId": "OG001", "value": "-13.64", "spread": "1.89"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-17.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.91", "ciUpperLimit": "-11.21", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.98", "estimateComment": "Evolocumab - Placebo"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in VLDL-C at Week 12", "populationDescription": "Randomized participants who received at least 1 dose of the study drug (placebo or evolocumab).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks."}, {"id": "OG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "280"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.02", "spread": "2.94"}, {"groupId": "OG001", "value": "-10.31", "spread": "2.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.", "pValue": "<0.0001", "statisticalMethod": "Repeated measures linear effects model", "statisticalComment": "Model includes treatment group, stratification factor (screening LDL-C level), scheduled visit and the interaction of treatment with scheduled visit.", "paramType": "LS Mean Treatment Difference", "paramValue": "-13.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.09", "ciUpperLimit": "-6.56", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.44", "estimateComment": "Evolocumab - Placebo"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "From the first dose of study drug (placebo or evolocumab) to week 12.", "description": "Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 141, "seriousNumAffected": 2, "seriousNumAtRisk": 141, "otherNumAffected": 19, "otherNumAtRisk": 141}, {"id": "EG001", "title": "Evolocumab", "description": "Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.", "deathsNumAffected": 1, "deathsNumAtRisk": 280, "seriousNumAffected": 14, "seriousNumAtRisk": 280, "otherNumAffected": 37, "otherNumAtRisk": 280}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}]}, {"term": "Peptic ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Osteomyelitis chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Fracture displacement", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "B-cell lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 280}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 280}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 280}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 280}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 280}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 280}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 280}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."}, "pointOfContact": {"title": "Study Director", "organization": "Amgen Inc.", "email": "medinfo@amgen.com", "phone": "866-572-6436"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-01-06", "uploadDate": "2018-08-02T20:36", "filename": "Prot_000.pdf", "size": 2008107}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2016-12-22", "uploadDate": "2018-08-02T20:36", "filename": "SAP_001.pdf", "size": 746685}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000006937", "term": "Hypercholesterolemia"}, {"id": "D000050171", "term": "Dyslipidemias"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006949", "term": "Hyperlipidemias"}, {"id": "D000052439", "term": "Lipid Metabolism Disorders"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M26181", "name": "Dyslipidemias", "asFound": "Dyslipidemia", "relevance": "HIGH"}, {"id": "M9988", "name": "Hypercholesterolemia", "asFound": "Hypercholesterolemia", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M10000", "name": "Hyperlipidemias", "relevance": "LOW"}, {"id": "M10002", "name": "Hyperlipoproteinemias", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000577155", "term": "Evolocumab"}, {"id": "D000000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D000091362", "term": "PCSK9 Inhibitors"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000015842", "term": "Serine Proteinase Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M348166", "name": "Evolocumab", "asFound": "Laparoscopic Surgery", "relevance": "HIGH"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Laparoscopic Surgery", "relevance": "HIGH"}, {"id": "M2849", "name": "PCSK9 Inhibitors", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M18391", "name": "Serine Proteinase Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "T18", "name": "Serine", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}